GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
The company secures funding to push its lead candidate towards US approval.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
ELVN-001 is made to look more like Terns’ TERN-701.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
Four months after yielding first-in-human data INCA33890 enters phase 3.
